Around the Net
Bristol-Myers Squibb Settles Over Abilify Marketing
- Associated Press, Monday, December 12, 2016 8 AM
Bristol-Myers Squibb Co. will pay $19.5 million to settle allegations that it promoted the anti-psychotic drug Abilify for unapproved uses and misled doctors about its dangers. New York-based Bristol-Myers Squibb denies any wrongdoing but agreed to various marketing restraints.
